General Medicine Classics

Physician-written reports of landmark medical studies

Classics Series, Landmark Trials in Medicine

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

1. Previous studies suggest that intensive blood glucose control reduces the risk of microvascular complications, though questions remained regarding the impact on macrovascular complications...
Classics Series, Landmark Trials in Medicine

The TRICC trial: Restrictive transfusion in intensive care does not increase mortality [Classics Series]

1. Using a restrictive transfusion strategy in critically ill patients did not significantly increase 30-day mortality when compared with a liberal transfusion strategy. 2. Subgroup...
Classics Series, Landmark Trials in Medicine

The RALES trial: Spironolactone decreases all-cause mortality in heart failure patients [Classics Series]

Image: PD 1. Adding 25 mg of spironolactone to standard therapy reduces all-cause mortality in heart failure patients with an ejection fraction <35% Original Date of...
Classics Series, Landmark Trials in Medicine

The AFFIRM trial: Rate-control vs. rhythm-control in atrial fibrillation [Classics Series]

1. Rate-control, along with anticoagulation, should be the main approach to managing patients with atrial fibrillation. 2. Compared to rhythm-control, rate-control resulted in a lower...
Classics Series, Landmark Trials in Medicine

The CLOT trial: Dalteparin versus warfarin [Classics Series]

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials, 1e (The Classics Series). 1....
Classics Series, Landmark Trials in Medicine

The RACE-II trial: Lenient vs. strict rate-control in atrial fibrillation [Classics Series]

1. Lenient rate-control was found to be non-inferior to strict rate-control in managing patients with atrial fibrillation. 2. Compared to strict rate-control, lenient rate-control could...
Classics Series, Landmark Trials in Medicine

The HOPE trial: Ramipril significantly reduces cardiovascular events in high-risk patients with normal ejection...

Image: CC/L. academia 1. Ramipril significantly reduces cardiovascular events including MI, stroke and death in high risk-patients in the absence of left ventricular dysfunction Original Date...
Classics Series, Landmark Trials in Medicine

The ALLHAT: Thiazide diuretics as first-line antihypertensive therapy [Classics Series]

1. There were no significant differences in the rates of fatal coronary heart disease or nonfatal myocardial infarction when comparing thiazide diuretics with ACE-Is...
Classics Series, Landmark Trials in Medicine

The RE-LY trial: Dabigatran non-inferior to warfarin in preventing strokes in patients with atrial...

Image: CC/L. academia 1. High-dose dabigatran is superior to warfarin in the prevention of strokes in patients with atrial fibrillation, while low-dose dabigatran is non-inferior...
Classics Series, Landmark Trials in Medicine

The JUPITER: Rosuvastatin in healthy patients with elevated CRP levels [Classics Series]

1. In patients with average LDL cholesterol levels and elevated CRP, rosuvastatin significantly reduced the risk of a first major cardiovascular event compared to...
licensing as small

All-time hits